The UAE and Saudi Arabia are no longer peripheral markets when it comes to clinical research. Over the past few years, both have taken deliberate steps to position themselves as credible, internationally aligned locations for the conduct of clinical trials, a shift that is increasingly visible and attractive to global pharmaceutical sponsors.
This momentum is closely linked to national policy. Saudi Arabia’s Vision 2030 and the UAE’s Centennial 2071 are not simply economic roadmaps; they explicitly prioritise healthcare innovation, scientific research, and the development of knowledge-based economies. Clinical trials are increasingly recognised as a core component of that ambition, both as a means of improving patient outcomes locally and as a way of embedding these jurisdictions into global research pipelines.
From opacity to procedural clarity in practice
One of the most notable developments in both countries is the gradual move away from opaque or ad hoc approval processes towards codified, structured regulatory frameworks. While neither jurisdiction could be described as “light-touch”, sponsors now benefit from clearer documentation requirements, defined approval pathways, and increasing alignment with international standards such as the ICH Guidelines for Good Clinical Practice.
This regulatory maturation has coincided with significant growth in the regional pharmaceutical market, with multiple forecasts pointing to sustained expansion through to 2030. Multinational pharmaceutical companies are correspondingly deepening their presence in the region, not only through commercial operations but also through partnerships with hospitals, academic institutions, and Contract Research Organizations (CROs) that support clinical research and evidence generation.
Patient populations and study design
From a scientific and operational perspective, the Middle East presents compelling trial conditions. High prevalence of chronic diseases, including diabetes, cardiovascular disease, and oncology indications, creates both unmet medical need and access to relevant patient populations.
In addition, the geographic position of the UAE and Saudi Arabia at the intersection of Europe, Asia, and Africa supports recruitment from diverse populations. For sponsors running multi-centre or international trials, this can enhance enrolment efficiency and the generalisability of data, particularly where ethnicity, lifestyle, and comorbidity profiles are relevant to outcomes.
Regulatory oversight: different systems, similar direction of travel
In Saudi Arabia, clinical trials involving pharmaceuticals fall under the oversight of the Saudi Food and Drug Authority, working alongside the Ministry of Health and with ethical oversight from local Institutional Review Boards and the National Committee of Bioethics. Saudi Arabia also operates the Saudi Clinical Trials Registry, a publicly accessible platform that reflects increasing transparency and international alignment.
Saudi sponsors and CROs will recognise a structured, phase-specific submission process, with particular flexibility for Phase IV and post-authorisation studies, an area of growing importance for real-world evidence strategies.
In the UAE, the framework is federal but operationally decentralised, which reflects the Emirate and Free Zone based jurisdictional fragmentation. Clinical research sits within a national framework historically overseen by the Ministry of Health and Prevention (MOHAP), with Emirate-level authorities such as the Abu Dhabi Department of Health and the Dubai Health Authority exercising jurisdiction within their territories, as well as specific healthcare free zones such as the Dubai Healthcare City, which operate their own regulatory regimes for clinical research. In parallel, the Emirates Drug Establishment has been established as a federal authority with a mandate that includes developing a national framework for pharmaceutical research and clinical trials, with implementation continuing as responsibilities transition from MOHAP.
For sponsors, the practical reality is that approvals often involve multiple regulatory and ethics layers, with the precise pathway determined by where the trial is conducted, including whether it sits within a specific Emirate or a healthcare free zone, and by the nature of the study.
Practical points sponsors need to get right
Across both jurisdictions, several core principles apply:
- Study classification and scope. While both interventional and observational studies are permitted, correct classification at the outset is critical. In practice, mischaracterisation can lead to re-submission, fee exposure, or delays, particularly for Phase IV and real-world evidence studies.
- Informed consent localisation. Robust informed consent is central to ethics approval which draws upon the emerging data privacy regime which sits alongside various health data laws. Participant-facing materials are expected to be available in Arabic and English, with enhanced safeguards in certain circumstances and close scrutiny of how global templates are adapted for local use.
- Sponsor structure and CRO delegation. Sponsors remain legally accountable for trial conduct and data integrity, even where regulatory interactions and operational activities are delegated to a local CRO. Where the sponsor has no local entity, careful structuring of CRO roles and regulatory interfaces is essential.
- Export of investigational products and bio-samples. Import and export of investigational medicinal products and biological samples is permitted in both jurisdictions, but subject to defined regulatory and ethics approvals. In Saudi Arabia, the export of biological samples is particularly closely scrutinised. In practice, sponsors must demonstrate that the relevant diagnostic or research objectives cannot reasonably be met locally, and approvals are granted on a case-by-case basis, with regulators and ethics committees retaining discretion to assess the proposed rationale and the wider benefit to Saudi society. Sponsors should therefore address sample export strategy, regulatory justification, and participant consent at an early stage of study design.
A maturing, but still evolving, regulatory landscape
While the direction of travel is clear, these frameworks remain relatively nascent. Sponsors can still expect to encounter areas of ambiguity, overlapping regulatory jurisdictions and limited precedent, particularly in relation to novel study designs, decentralised trials, or complex data and sample flows. The limited availability of judicial and administrative reviews and escalation channels also results in nuanced risk considerations for multinational sponsors who are less familiar with local norms.
In practice, sponsors that engage early with experienced local CROs, ethics committees, and regulatory counsel who understand the sector are best placed to navigate these issues efficiently. With the right structuring and local insight, both the UAE and Saudi Arabia offer increasingly sophisticated environments for high-quality, ethically robust clinical research. For life sciences companies developing regional or global trial strategies, early legal input can be decisive in avoiding delays and unlocking these opportunities.
